GW Pharmaceuticals’ FDA Win Reinforces BofA’s Bullish Thesis

The U.S. Food and Drug Administration approval of GW Pharmaceuticals PLC (NASDAQ: GWPH)’s epidiolex therapy for the treatment of seizures was expected — and reinforces the bullish case for owning the stock, according to Bank of America Merrill Lynch. Continue reading “GW Pharmaceuticals’ FDA Win Reinforces BofA’s Bullish Thesis”